Roger G. Harrison
The general area of my research is the application of biotechnology to solve medical problems. Toward this end, my research group has developed significant expertise in the engineering, expression, and purification of recombinant proteins produced in Escherichia coli bacteria. We developed the NusA fusion protein system for expressing recombinant proteins in soluble form, which has been licensed by the University of Oklahoma to a biotechnology company for the worldwide research market. A major emphasis of my current research is the development of new fusion proteins for the treatment of cancer, obesity, and hemophilia.
In one project for cancer treatment, we are targeting the enzyme methioninase to tumors, with the objective of cutting off the supply of the amino acid methionine to the tumor. Tumor cells of all types have an elevated requirement for methionine compared to normal cells. Many cancer cell lines are unable to survive when methionine is replaced in the medium with homocystine; however, normal cell lines grow well with this substitution.
In another project, we are targeting conjugates of recombinant proteins and single-walled carbon nanotubes (SWNTs) to tumors. SWNTs are unique in that they strongly absorb near-infrared light, while biological systems have very low levels of absorption of NIR light. The targeting of SNWTs to tumors and subsequent application of NIR light will allow the selective elimination of tumors.
Research Web Sites
Bioengineering Center - Home Page
Bioseparations Science and Engineering Textbook
“Retention of Biological Activity and Near-Infrared Absorbance upon Adsorption of Horseradish Peroxidase on Single-Walled Carbon Nanotubes,” (with N.R. Palwai, D.E. Martyn, L.F.F. Neves, Y. Tan, and D.E. Resasco), Nanotechnology, 18, 235,601, (2007).
“Targeting a Methioninase-containing Fusion Protein to Breast Cancer Urokinase Receptors Inhibits Growth and Migration,” (with X.P. Zang, N.R. Palwai, M.R. Lerner, D.J. Brackett, and J.T. Pento), Anticancer Research 26, 1745 (2006).
“Internalizing versus Non-Internalizing Receptors for Targeting L-Methioninase to Cancer Cells,” (with X.P. Zang, N.R. Palwai, and J.T. Pento), Am. J. Pharmcol. Toxicol., 1, 60 (2006).
“A Soluble Tissue Factor-Annexin V Chimeric Protein Has Procoagulant and Anticoagulant Properties,” (with X. Huang, W.Q. Ding, J. Vaught, R. Wolf, J.H. Morrissey, and S.E. Lind), Blood, 107, 980 (2006).
Bioseparations Science and Engineering, (with P. Todd, S.R. Rudge, and D. Petrides), Oxford University Press, New York (2003).
“Targeting of a Novel Fusion Protein Containing Methioninase to the Urokinase Receptors to Inhibit Breast Cancer Cell Migration and Proliferation,” (with K. Peron, T.N. Jones, S.A. Gauthier, T.T. Nguyen,X.P. Zang, M. Barriere, D. Prévéraud, C.E. Soliman, and J.T. Pento), Cancer. Chemother. Pharmacol., 52, 270 (2003).
“New Fusion Protein Systems Designed to Give Soluble Expression in Escherichia coli,” (with G.D. Davis, C. Elisee, and D.M. Newham), Biotech. Bioeng., 65, 382 (1999).
Protein Purification Process Engineering, R.G. Harrison (Ed.), Marcel Dekker, New York (1993).